




Acridinium

Revised: December 3, 2018.

CASRN: 727649-81-2



Drug Levels and Effects

Summary of Use during Lactation

Although no published data exist on the use of acridinium during breastfeeding, it produces low maternal serum levels because of rapid hydrolysis to inactive metabolites. The risk to the breastfed infant of maternal acridinium inhalation is small.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Tiotropium, Umeclidinium

Substance Identification

Substance Name

Acclidinium

CAS Registry Number

727649-81-2

Drug Class

Breast Feeding

Lactation

Anti-Asthmatic Agents

Parasympatholytics

Muscarinic Antagonists

Bronchodilator Agents